DUBLIN, Jan. 4, 2022 /PRNewswire/ — The “Immunohistochemistry Market Forecast to 2028 – COVID-19 Impact & Global Analysis by Application (Diagnostics, and Drug Testing); Product (Antibodies, Equipment, Reagents, and Kits); End User (Hospitals and Diagnostic Laboratories, Research Institutes, and Others), & Geography” report has been added to ResearchAndMarkets.com’s offering.
The immunohistochemistry market is expected to reach US$ 3,585.31 million by 2028 from US$ 2,171.61 million in 2021; it is estimated to register a CAGR of 7.4% from 2021 to 2028.
Rising incidence of chronic and infectious diseases, increasing geriatric population, and rising R&D investments by biotechnology and biopharmaceutical companies are the key factors driving the market. However, the limitations associated with immunohistochemistry are hindering the market growth.
Immunohistochemistry (IHC) refers to an important application of monoclonal and polyclonal antibodies for tissue determination and distribution of antigens of a particular disease. It is majorly used to detect several infectious disorders such as dengue, hepatitis, and AIDS. Immunohistochemistry helps diagnose chronic medical conditions like obesity, cancer, diabetes, heart disease, and stroke.
According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), 37.6 million people across the globe had HIV in 2020. 35.9 million were adults, and 1.7 million were children (< 15 years old). An estimated 1.5 million individuals worldwide…
